Gene selection for genomic newborn screening: moving towards consensus?

BACKGROUND:Gene selection for genomic newborn screening (gNBS) underpins the validity, acceptability, and ethical application of this technology. Existing gNBS gene lists are highly variable despite being based on shared principles of gene-disease validity, treatability, and age of onset. AIM:To curate a gNBS gene list that builds upon existing efforts and provide a core consensus list of gene-disease pairs assessed by multiple expert groups worldwide. METHODS:Our multidisciplinary expert team curated a gene list using an open platform and multiple existing curated resources. We included severe treatable disorders with age of disease onset <5years with established gene-disease associations and reliable variant detection. We compared the final list with published lists from five other gNBS projects to determine consensus genes and to identify areas of discrepancy. RESULTS:We reviewed 1279 genes and 604 met our inclusion criteria. Metabolic conditions comprised the largest group (25%), followed by immunodeficiencies (21%) and endocrine disorders (15%). We identified 55 consensus genes included by all six gNBS research projects. Common reasons for discrepancy included variable definitions of treatability and strength of gene-disease association. CONCLUSION:We have identified a consensus gene list for gNBS that can be used as a basis for systematic harmonization efforts internationally.